KUALA LUMPUR (Sept 23): Solution Group Bhd's subsidiary Solution Biologics Sdn Bhd and China-based CanSino Biologics Inc today signed a registration, manufacturing and commercialisation agreement, which will enable Solution Biologics to market and distribute in Malaysia the novel coronavirus vaccine developed by CanSino.
In a statement to Bursa Malaysia today, Solution Group said Solution Biologics will register with Malaysia's National Pharmaceutical Regulatory Agency to apply for the market authorisation certificate.
Solution Group said Solution Biologics "will establish a state-of-the-art fill and finish facility" to host a technology transfer for the filling, finishing and final quality control of CanSino's recombinant novel coronavirus vaccine.
The facility will be established at Solution Biologics' current premises at PT13796, Jalan Tekno Usahawan 2, Technology Park Malaysia in Bukit Jalil here.
"CanSino will collaborate with Solution Biologics in obtaining the necessary approvals [including the marketing authorisation] for the purposes of the registration and commercialisation of the product in Malaysia.
"Upon the product's registration, CanSino will be partnering with Solution Biologics in supplying to Solution Biologics of bulk product for further manufacturing (fill and finish) of the finished product, its final quality control release and its commercialisation by Solution Biologics in Malaysia," Solution Group said.
"Upon the successful implementation of the terms, interests and the intention of the parties as set out in the agreement, Solution Group expects the collaboration will contribute positively to its earnings in the future," Solution Group said.
At 3.14pm today, Solution Group's share price rose four sen or 5.8% to 73 sen for a market capitalisation of RM223.51 million. The stock saw some 107 million shares traded.